Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors In Phase III NSCLC Trial

  1. 家
  2. 國際的
  3. 美國
  4. 奧斯汀
  5. 商業（B2B）
  6. 企業出售
  1. Posted by: [email protected]
  2. Member since: June 2026
  3. Posted:
  4. 類別: 企業出售
  5. 地區: 奧斯汀 (Astin)
  6. 發帖編號: 63684214
Genentech’s Phase III Krascendo 1 trial shows divarasib significantly improves progression-free survival over approved KRAS G12C inhibitors in advanced NSCLC patients.

Austin, Businesses For Sale, Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors In Phase III NSCLC Trial
返回 下一個
給朋友發電子郵件

Ask AI to Review This Ad

這個廣告有問題嗎？


How to Avoid Scams